Introduction
hospital because of graft dysfunction of unknown origin Elevated IL-6 concentrations were always confirmed by blocking experiments (data not shown) with biologically were followed from the day of admission until the day of discharge. Graft dysfunction was defined as an increase in active mouse monoclonal antibodies and by ELISA (R&D Systems, Quantikine human IL-6 immunoassay; sensitivity serum creatinine >0.5 mg/dl within 2 days. Samples from 37 patients with stable graft function (stable serum creatinine threshold as stated by the manufacturer, 3.5 pg/ml ). The antibodies were: (1) Chemicon International Inc., Temecula, <2 mg/dl, no adverse event), as well as samples from 20 healthy volunteers, were used as controls.
California, USA, 100 mg/ml; (2 ) Boehringer Mannheim GmbH, Mannheim, Germany, 100 mg/ml; (3 ) DianovaStandard immunosuppressive therapy consisted of CsA and methylprednisolone (MP). MP was given as a bolus of Immunotech GmbH, Hamburg, Germany, 100 mg/ml. The soluble form of the IL-6R was measured by a specific enzyme 250 mg intravenously before transplantation, 100 mg on day 1, 60 mg for the next 3 days, 40 mg within the first week. linked immunosorbent ( ELISA) assay ( R&D Systems, Quantikine human IL-6sR immunoassay; sensitivity threshThereafter, the drug was reduced in a stepwise fashion to 4 mg/day, 6 months after transplantation. CsA was adjusted old as stated by the manufacturer, 3.5 pg/ml ). This ELISA recognizes the free and the IL-6-associated form of the according to whole-blood trough levels to between 100 and 150 ng/ml ( TDX, Abbott Co., Wiesbaden, Germany). IL-6sR. Rejection episodes were routinely treated with intravenous MP boluses (250 mg/day) for 3 days. Steroid-resistant rejec-Immunohistochemistry tions were treated with antithymocyte globulin ( ATG, Fresenius, Bad Homburg, Germany: 4-6 mg/kg) for 10 days. Biopsy tissue was snap frozen in liquid nitrogen and stored Serum and urine samples from all 145 patients were at −70°C. For immunohistochemical staining frozen sections collected sequentially, at least three times per week between (6 mm) were air dried (1 h, room temperature) and fixed in 8:00 and 9:00 in the morning. Samples from outpatients with acetone (10 min, −20°C ). After incubation with a primary unknown graft dysfunction were collected before performing mouse monoclonal antibody (diluted in CM, 10% FCS, 30 renal biopsy. Within 1 h, all samples were centrifuged for min), the slides were incubated with a second rabbit anti-10 min (serum 600 g, urine 1000 g). The supernatants were mouse antibody (DAKO Diagnostika GmbH, Hamburg, stored at −20°C. From all patients 24-h urines were collected Germany, 100 mg/ml in 0.5% BSA/TBS, 30 min). Finally the in order to calculate the daily amount of IL-6 excretion.
APAAP complex ( Dako, 1 mg/ml in TBS, 30 min) was added. From 104 episodes of rejection, 80 occurred within the Neufuchsin substrate (Dako) was applied according to the first 2 months after transplantation, while 24 occurred more manufacturer's guidelines and the slides were counterstained than 2 months after transplantation. Rejection was confirmed for 1 min with haematoxylin (Sigma, St Louis, MO, USA). on histopathological grounds according to the Banff working All incubation steps were performed at room temperature. classification [23 ] . In 108 biopsies, we found 86 acute rejec-Between each step, the slides were washed twice in TBS. A tions (mild: n=49; moderate: n=15; severe: n=22) and 7 monoclonal antibody (IgG1) against CD45 was used as chronic rejections. Acute tubular necrosis (ATN ) was dia-positive control (Serotec, Oxford, UK, 25 mg/ml ). As negagnosed in 23 cases, of which 14 were in combination with tive control, we used a mouse monoclonal antibody ( IgG1) mild acute rejection and three were combined with moderate directed towards Aspergillus niger glucose-oxidase, an enzyme acute rejection. CsA nephrotoxicity was diagnosed in only that is neither present nor inducible in mammalian tissues, one case. Eight biopsies showed borderline or non-specific (Dako, 50 mg/ml ). The healthy part of human kidneys changes requiring no rejection treatment. In 11 patients with nephrectomized because of hypernephroma was used as an clinically diagnosed rejection (unexplained increase in additional negative control. Cytokine expression was quantiserum creatinine concentration >0.5 mg/dl within 2 days), fied by calculating the mean number of positive cells in four biopsy tissue was not sufficient or no biopsy was performed. randomly chosen vision fields per biopsy. Bacterial infections (n=55) were diagnosed according to Two primary mouse monoclonal antibodies against IL-6 standard culture criteria including a positive tissue culture. (IgG1) were applied (Chemicon International Inc., Temecula, Cytomegalovirus (CMV ) infection (n=9) was diagnosed by CA, USA, 50 mg/ml; Genzyme Diagnostics, Cambridge, MA, polymerase chain reaction (PCR) from heparinized blood.
USA, 100 mg/ml ). For IL-6R staining, three mouse monoclonal antibodies (IgG1) against gp80 were used (Biosource International, Camarillo, CA, USA, 50 mg/ml ).
Cytokine assays Statistics
We employed a bioassay using the IL-6 dependent cell line B9 [24] . To reduce intertest variability, all samples from one All data are expressed as mean±standard error of the mean patient were tested together within 2 months. Some 5000 B9 (SEM). Statistical significance for dependent variables was cells were seeded into each well of a 96-well microtitre plate assessed by Wilcoxon test. Statistical significance for inde-( Falcon, Becton Dickinson, New Jersey, USA) in 50 ml pendent variables was evaluated by the Mann-Whitney complete Click's medium (CM, 10% fetal calf serum FCS). U-test and Kruskal-Wallis test. Transplant survival and For sterile filtration, serum or urine was passed through a patient survival were evaluated according to Kaplan-Meier microfilter ( 0.22 mm). Serum samples were additionally inac-with a log-rank test. A probability of less than 0.05 was tivated by incubation at 56°C (30 min). A total of 50 ml considered as statistically significant. sample in CM were added to the B9 cells in triplicates (final concentration: serum 10%, urine 2.5%). The plates were
Results incubated for 72 h (37°C, 5% CO 2 , 97% humidity) before cell proliferation was measured by MTT assay as described elsewhere [ 25] . B9 cells were incubated with 10 ml of MTT IL-6 expression in serum solution (0.5% in PBS) for 4 h. After lysis by SDS (10% in
The mean IL-6 concentration in serum was 0.01% HCl ) optical density was evaluated at 570 nm. For this bioassay the threshould of sensitivity was 0,5 pg/ml. 3.5±1.1 pg/ml in healthy volunteers, 3.3±2.3 pg/ml in IL-6 expression after renal transplantation 755 transplanted patients with stable graft function, and 8.6±2.7 pg/ml in patients with minimal graft dysfunction. This designation was based on histopathological investigations, showing no, non-specific, or only very borderline changes ( Figure 1 ). Within the first 2 months after transplantation, the serum concentrations (<3 days before diagnosis) were significantly elevated during rejection ( 17±4.8 pg/ml; P<0.05) compared to normal values ( Figures 1, 2) . After successful rejection treatment, IL-6 concentrations returned to normal ( 0-5 pg/ml; P<0.05). In case of therapy resistant rejection (n=11), elevated IL-6 concentrations persisted (>5 pg/ml; P<0.05). Subdivision according to the Banff classification revealed a trend (P=n.s.) towards higher IL-6 concentrations during mild ( 21±7.9 pg/ml ) and moderate acute rejections ( 17±11 pg/ml ) compared to values measured during severe acute rejections (9.7±4.4 pg/ml ) ( Figure 1 ). Rejection episodes were detected with a sensitivity of 54% and a specificity of 70% (threshold IL-6 concentration: 5 pg/ml ). More than 2 months after transplanta- Fig. 2 . Serum and urinary IL-6 concentrations before (10-4 days, tion, IL-6 serum concentrations during rejection (<3 3-0 days), during (1-2 days) and after ( 3-10 days) rejection therapy within the first 2 months after transplantation.
days before diagnosis) were not significantly elevated ( 9.6±2.6 pg/ml; P=n.s.) (Figure 1 ). Infections ( 19±4.4 pg/ml; P<0.05) also induced significantly nephrotoxicity ( 4.7 pg/ml ) had no significant effect elevated IL-6 serum concentrations ( Figure 1 ). (Figure 1 ). Histologically defined chronic rejection (7.8±2.7 pg/ ml; P=n.s.), ATN ( 9.4±1.9 pg/ml; P=n.s.), and CsA IL-6 expression in urine
In urine the mean IL-6 concentration was 2.1±0.7 pg/ml in healthy volunteers and 3.9±0.7 pg/ml in transplanted patients with stable graft function ( Figure 3 ). In patients with borderline graft dysfunction (above criteria), the mean IL-6 concentration was 2.7±1.3 pg/ml (Figure 3 ) . During rejection episodes within the first 2 months after trans- Fig. 1 . Comparison of serum IL-6 concentrations 3-0 days before different adverse events. Control, control persons; stable, patients with stable graft function; borderline, graft dysfunction with histopathological investigation showing no, non-specific or only borderline changes; early rej, rejection <2 months after transplantation; mild, mild early rejection; moderate, moderate early rejection; severe, severe early rejection; late rej, rejection >2 months after transplantation; chron rej, histologically proven chronic rejection; ATN, acute plantation, urinary IL-6 concentration (<3 days before significant increase (<3 days before diagnosis) was diagnosis) was significantly elevated (115±27 pg/ml; found during rejection episodes (∏2 months after P<0.005) ( Figures 2, 3 ) . After successful rejection transplantation: 55±5.8 ng/ml, P=n.s.; >2 months treatment, IL-6 concentrations returned to normal after transplantation: 47±8.6 ng/ml, P=n.s.) and ( 0-5 pg/ml; P<0.001). In case of therapy resistant during infection (57±3.9 ng/ml; P=n.s.). During ATN rejection (n=11), elevated IL-6 concentrations per-there was a trend towards elevated serum IL-6sR sisted (>5 pg/ml; P<0.05). Subdivision according to concentrations ( 74±18 ng/ml; P=n.s.). In urine, the the Banff classification revealed a trend (P=n.s.) IL-6sR concentrations of patients with stable graft towards higher IL-6 concentrations during mild function were significantly reduced compared to ( 155±49 pg/ml ) and moderate acute rejection (129± healthy volunteers (285±180 vs 1315±144 pg/ml; 51 pg/ml ) compared to severe acute rejection (25± P<0.05). A significant increase was found during 6.1 pg/ml ) (Figure 3 ). Rejection episodes were urinary tract infections ( 1066±176 pg/ml; P<0.05). detected with a sensitivity of 93% and a specificity of During rejection episodes occurring less than 2 months 60% (threshold IL-6 concentration: 5 pg/ml ). Using a after transplantation (835±156 pg/ml ) and during threshold IL-6 concentration of 10 pg/ml, specificity those occurring more than 2 months after transplantawas 71% and sensitivity 87%. During rejection episodes tion ( 965±329 pg/ml ), there was only a trend (P= more than 2 months after transplantation, IL-6 concen-n.s.) towards higher IL-6sR concentrations. ATN trations were only slightly elevated (17±6.6 pg/ml; (441±51 pg/ml ) did not cause significant changes P=n.s.) ( Figure 3 ). During infection (74±15 pg/ml ) (P=n.s.). and ATN (111±49 pg/ml ) elevated urinary IL-6 concentrations (P<0.05) were also found (Figure 3 ). In patients with acute rejection (115±27 pg/ml ), the presence of ATN seemed to have an additional effect Immunohistochemistry ( 226±76 pg/ml; P=n.s.) further increasing IL-6 concentrations ( Figure 3 ). Histologically defined chronic None of the negative controls showed significant stainrejection (16±12 pg/ml; P=n.s.) and CsA nephrotox-ing. Of 108 transplant biopsies, 103 stained positive icity (2.4 pg/ml ) did not cause significant changes for IL-6 and 101 stained positive for IL-6R. We are ( Figure 3 ). unable to explain the negative staining of five negative The finding that rejection episodes during the first 2 IL-6 and 7 negative IL-6R biopsies; each biopsy had months after transplantation reduced urinary volume different histopathological diagnoses. IL-6 staining was from 1.8±0.2 l/day to 1.4±0.1 l/day (P<0.05) raised located in the cytoplasm of cells. Most of the IL-6 the question whether or not elevated IL-6 concentra-positivity was seen on the edges of the interstitial tions were related to urinary volume. Therefore, we infiltrate ( Figure 4a ) and in the periglomerular area calculated the daily amount of IL-6 excretion. During (Figure 4b ). The number of IL-6 positive cells per field acute rejection within 2 months after transplantation, ranged from 5 to 300 with a mean value of 52±7.3. the total amount of excreted IL-6 rose from IL-6 expression during acute rejection episodes within 12±3.3 ng/24 h to 127±50 ng/24 h (P<0.05). To fur-the first 2 months after transplantation (53±6,4) was ther exclude the possibility that urinary IL-6 concentra-not different from rejection events >2 months after tions was dependent on renal concentration capacity, transplantation (49±4,2; P=n.s.). In several cases, we also calculated the IL-6 excretion rate, defined as tubular epithelial cells (24/108; Figure 4c ) and cells the ratio of urinary IL-6 concentration ( pg/ml ) to within the glomerular area (12/108; Figure 4b ) also urinary creatinine concentration (mg/dl ). Patients with stained positive. Many CD45 positive cells were found stable graft function had an IL-6 excretion rate of within these glomeruli. Thus, the intraglomerular IL-6 6.9±4.6 (×10-7). During rejection episodes within the expression was likely caused by infiltrating monofirst 2 months, the IL-6 excretion rate was significantly nuclear cells. Interstitial tissue and the vasculature elevated (212±66 (×10-7) ; P<0.05).
invariably stained negative. Regression analysis of the Mean allograft survival was mainly influenced by number of IL-6 positive cells in tissue and the concenthe frequency of rejection episodes (no rejection:
tration of IL-6 in serum/urine did not show any 1152±88 days; 1 rejection: 982±62 days; >1 rejection: correlation (r=0.05/r=0.23). Furthermore, the 526±137 days; P<0.01). Therefore, we also investinumber of IL-6 positive cells did not correlate with gated whether or not repeated rejections could be the histological diagnosis according to the Banff classipredicted by the urinary IL-6 concentration. However, fication (r=0.16). The distribution pattern of IL-6R urinary IL-6 concentration had no predictive value on resembled the IL-6 pattern. Most staining was found rejection frequency, 1-year graft function and 1-year in mononuclear cells around the interstitial infiltrate graft survival (P=n.s.).
( Figure 4d ). The number of positive cells ranged from 4 to 200 with a mean value of 59±23. The positive IL-6sR measurements cell number neither correlated with IL-6sR concentrations in serum or urine, nor with the histopathological In serum, the concentration of IL-6sR was diagnosis. The vasculature, the tubular cells and the 35±1.8 ng/ml in healthy volunteers and 49±5.9 ng/ml in transplanted patients with stable graft function. No glomeruli were always negative. sensitive parameter of allograft rejection (93%).
Discussion
Elevated IL-6 concentrations were found 0-3 days before the diagnosis of rejection was made, i.e. 0-3 Our findings support earlier work [15] [16] [17] [18] [19] [20] [21] showing days before a significant rise in serum creatinine that IL-6 concentrations in serum and in urine are (>0.5 mg/dl ) was detectable. Extending previous elevated during episodes of acute graft rejection. We reports [18] [19] [20] [21] , we were able to show that this elevaobserved significant changes only within the first 2 tion was not due to changes in renal function. In the months after transplantation. This finding suggests peripheral circulation, IL-6 exists in the form of highthat IL-6 is mainly involved in early acute rejection. molecular-weight complexes with other proteins, Persisting elevations indicated therapy-resistant rejecincluding fragments of the C-reactive protein, the tion, while successful rejection treatment reduced IL-6 soluble IL-6 receptor, and components of the compleconcentrations to normal. Several investigations ment C4B and C3C [26] [27] [28] . The greater success in [15] [16] [17] 19] have concluded that sequential IL-6 serum predicting rejection using urine as opposed to serum measurements might be a useful parameter for the could be due to the possibility that the former does diagnosis of allograft rejection; however, their numbers not exist in multimeric forms and therefore might be of subjects were small. Newstead et al. [21] could not more reflective of biologically relevant changes. confirm these results. We monitored a large number of Surprisingly, subdivision of rejection episodes patients (n=145) with sequential IL-6 serum measureaccording to the Banff classification [23] revealed a ments (Á3 per week) and compared these results with trend towards a negative correlation between the perihistopathological diagnosis according to Banff classipheral IL-6 concentration and rejection severity. fication [23] . The clinical course of our patients was
Vasculitis is the main feature of severe rejection [23 ] . statistically analysed. In agreement with Newstead As already reported by Raasveld et al. [14] , endotheet al.
[21] our results clearly indicate that sequential lium always stained negative for IL-6, even in cases of IL-6 serum measurements are of no value in predicting severe rejection. The recruitment of different cell types allograft rejection due to their low sensitivity ( 54%).
during different types of rejection might be the reason In contrast, elevated urinary IL-6 values during the first 2 months after transplantation proved to be a for this phenomenon. No correlation was found
